Dr Ariane Lewis discusses how we can navigate uncertainty and ambiguity about brain death by understanding clinical criteria for brain death determination and how our approaches to death are culturally and socially situated.
There is a market for direct-to-consumer genetic testing and a need for better consumer information and more regulation of tests and testing laboratories.
The question of whether and how results from personal genetic testing will motivate behavioral changes in consumers has only begun to receive the research attention it richly deserves.
